Olanzapine
- PDF / 151,121 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 71 Downloads / 165 Views
1 S
Sedation: case report A 29-year-old woman developed persistent sedation during treatment with olanzapine for paranoid schizophrenia. The woman presented with the first psychotic episode and was admitted to the psychiatric unit in the UK for treatment. She was born in Eritrea and migrated in 2008 to the UK due to civil unrest in the Eritrea. In September 2018 (4 months prior to this admission), she had delivered her first baby and had separated from her partner. She had been receiving unspecified antidepressants prescribed by her general physician for chronic depression and anxiety following sexual trauma at the age of 15 years. She was diagnosed with paranoid schizophrenia. Her risk factors included various bio-psychosocial circumstances. At current admission in 2019, she started receiving risperidone which was poorly tolerated. Therefore, within the first week, her risperidone was switched to oral olanzapine at the maximum dose of 20 mg/day. Despite six weeks of olanzapine treatment, she achieved incomplete response. She also developed persistent sedation and refused the treatment with olanzapine. The woman’s olanzapine was switched to trifluoperazine [trifluoperazine hydrochloride] resulting in significant improvement in her paranoia symptoms. Thereafter, she remained hospitalised due to unstable social factors, and a discharge planning meeting was under process. Sheikh A, et al. Mental disorders in migrants: First episode psychosis in postpartum period. Progress in Neurology and Psychiatry 24: 7-10, No. 2, 2020. Available from: 803504242 URL: http://doi.org/10.1002/pnp.662
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
